These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11737376)

  • 1. Assessing the cost-effectiveness of HAART for adults with HIV in England.
    Miners AH; Sabin CA; Trueman P; Youle M; Mocroft A; Johnson M; Beck EJ
    HIV Med; 2001 Jan; 2(1):52-8. PubMed ID: 11737376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
    Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
    Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom.
    Trueman P; Youle M; Sabin CA; Miners AH; Beck EJ
    HIV Clin Trials; 2000; 1(1):27-35. PubMed ID: 11590487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
    AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
    Llibre-Codina JM; Casado-Gómez MA; Sánchez-de la Rosa R; Pérez-Elías MJ; Santos-González J; Miralles-Alvarez C; Martínez-Chamorro E; Domingo-Pedrol P; Alvarez-García ML; Moreno-Guillén S
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):98-107. PubMed ID: 17288907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
    Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
    J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
    Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
    Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM
    JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center.
    Mole L; Ockrim K; Holodniy M
    Pharmacoeconomics; 1999 Sep; 16(3):307-15. PubMed ID: 10558042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
    Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
    Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.